Patents by Inventor Gerhard Seipke
Gerhard Seipke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9644017Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.Type: GrantFiled: June 22, 2010Date of Patent: May 9, 2017Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Gerhard Seipke, Roland Kurrle, Gunter Muller, Mark Sommerfeld, Norbert Tennagels, Georg Tschank, Ulrich Werner
-
Patent number: 8633156Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.Type: GrantFiled: June 22, 2010Date of Patent: January 21, 2014Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Gerhard Seipke, Roland Kurrle, Gunter Muller, Mark Sommerfeld, Norbert Tennagels, Georg Tschank, Ulrich Werner
-
Patent number: 8603970Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.Type: GrantFiled: June 22, 2010Date of Patent: December 10, 2013Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Gerhard Seipke, Roland Kurrle, Gunter Muller, Mark Sommerfeld, Norbert Tennagels, Georg Tschank, Ulrich Werner
-
Publication number: 20110173722Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.Type: ApplicationFiled: June 22, 2010Publication date: July 14, 2011Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Paul HABERMANN, Gerhard SEIPKE, Roland KURRLE, Gunter MULLER, Mark SOMMERFELD, Norbert TENNAGELS, Georg TSCHANK, Ulrich WERNER
-
Publication number: 20110077197Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.Type: ApplicationFiled: June 22, 2010Publication date: March 31, 2011Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Paul HABERMANN, Gerhard SEIPKE, Roland KURRLE, Gunter MULLER, Mark SOMMERFELD, Norbert TENNAGELS, Georg TSCHANK, Ulrich WERNER
-
Publication number: 20070099821Abstract: The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LysB3,GluB29 insulin to patients in need of this treatment.Type: ApplicationFiled: December 12, 2006Publication date: May 3, 2007Applicant: Sanofi-Aventis Deutschland GmbHInventors: Gerhard Seipke, Irini Rakatzi, Olaf Dransfeld, Jurgen Eekel
-
Publication number: 20060172923Abstract: The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LySB3,GluB29 insulin to patients in need of this treatment.Type: ApplicationFiled: April 6, 2006Publication date: August 3, 2006Applicant: Sanofi-Aventis Deutschland GmbHInventors: Gerhard Seipke, Irini Rakatzi, Olaf Dransfeld, Juergen Eckel
-
Publication number: 20050250676Abstract: The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LysB3,GluB29 insulin to patients in need of this treatment.Type: ApplicationFiled: July 11, 2005Publication date: November 10, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Gerhard Seipke, Irini Rakatzi, Olaf Dransfeld, Jurgen Eckel
-
Patent number: 6875589Abstract: A mini-proinsulin, in which the amino acid Arg bridges the A and the B chain instead of the C chain, shows insulin activity and is suitable for the preparation of pharmaceuticals for the treatment of diabetes mellitus. It can furthermore be converted into an insulin derivative simply using trypsin, the B chain of which is lengthened by Arg. This can be converted into insulin using carboxypeptidase B. Advantageously, however, the mini-proinsulin can also be converted to insulin directly in a one-pot process.Type: GrantFiled: March 10, 1995Date of Patent: April 5, 2005Assignee: Hoechst AktiengesellschaftInventors: Michael Dörschug, Paul Habermann, Gerhard Seipke, Eugen Uhlmann
-
Patent number: 6686177Abstract: The invention relates to insulin analogs exhibiting enhanced zinc binding capacity and to stable zinc complexes thereof having a retarded activity in comparison with human insulin. The invention further relates to a method for the production of said insulin analogs and to their use, particularly in pharmaceutical preparations for therapy of type I and type II diabetes mellitus.Type: GrantFiled: May 14, 2001Date of Patent: February 3, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Johann Ertl, Paul Habermann, Karl Geisen, Gerhard Seipke, Axel Wollmer
-
Patent number: 6534288Abstract: The invention relates to a precursor of human insulin or of an insulin analog of the formula I: Fus-B(1-30)-RDVP-Yn-A(1-21) (I); wherein Fus is an optionally present fusion portion; B(1-30) is a B chain of human insulin, Y is an amino acid chain which terminates with a basic amino acid at the C terminus; n is from 2 to 50 and indicates the length of the amino acid chain Y; and A(1-21) is an A chain of human insulin, and the A chain and/or the B chain can be modified by amino acid substitution, deletions and/or additions. The present invention also provides DNA coding for the above precursors, preparation and use of the instant precursors and DNA, and a process for preparing human insulin or an insulin analog.Type: GrantFiled: October 2, 2000Date of Patent: March 18, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Paul Habermann, Johann Ertl, Johannes Meiwes, Gerhard Seipke
-
Patent number: 6221633Abstract: The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.Type: GrantFiled: June 18, 1998Date of Patent: April 24, 2001Assignee: Aventis Pharma Deutschland GmbHInventors: Johann Ertl, Paul Habermann, Karl Geisen, Gerhard Seipke
-
Patent number: 6221837Abstract: Insulin derivatives with increased zinc binding where Z is a histidine residue or a peptide having 2 to 35 genetically encodable amino acid residues, having 1 to 5 histidine residues, are suitable for the production of pharmaceutical preparations for the treatment of diabetes. Insulins of the formula I form complexes with zinc++, comprising an insulin hexamer and approximately 5 to 9 mol of zinc++ per hexamer.Type: GrantFiled: July 25, 1997Date of Patent: April 24, 2001Assignee: Aventis Pharma Deutschland GmbHInventors: Johann Ertl, Paul Habermann, Karl Geisen, Gerhard Seipke
-
Patent number: 5674531Abstract: Nanoparticles containing an active substance and a ketalized polytartramidic acid, process for their preparation, and use thereof. Nanoparticles containing an active substance and a ketalized polytartramidic acid are suitable as vehicles for active substances, in particular for peptides and proteins. Processes for the preparation of the nanoparticles are described.Type: GrantFiled: March 7, 1995Date of Patent: October 7, 1997Assignee: Hoechst AktiengesellschaftInventors: Michael Ahlers, Axel Walch, Gerhard Seipke, Gregory Russell-Jones
-
Patent number: 5270176Abstract: The invention relates to a method for the preparation of polypeptides or proteins by enzymatic cleavage of the oligo- or polyglycine sequence of a fusion protein using an endoprotease.Type: GrantFiled: June 29, 1992Date of Patent: December 14, 1993Assignee: Hoechst AktiengesellschaftInventors: Michael Dorschug, Gerhard Seipke
-
Patent number: 4644057Abstract: The invention relates to a process for the cleavage of peptides and proteins at the methionyl bond using cyanogen chloride.Type: GrantFiled: November 7, 1985Date of Patent: February 17, 1987Assignee: Hoechst AktiengesellschaftInventors: Richard Bicker, Gerhard Seipke
-
Patent number: 4601852Abstract: What is disclosed is a method for making human insulin or modified human insulin from pig insulin or modified pig insulin by reacting the pig insulin starting material at a pH below its isoelectric point with an excess of a threonine ester in the presence of trypsin or a trypsin-like enzyme.Type: GrantFiled: August 15, 1984Date of Patent: July 22, 1986Assignee: Hoechst AktiengesellschaftInventors: Rainer Obermeier, Jurgen Ludwig, Gerhard Seipke
-
Patent number: 4526717Abstract: The invention relates to a polypeptide which can be isolated from thymus glands and has an action on the immunological system, and which has a molecular weight of 3,480, a UV absorption with a maximum at 205 to 210 nm and an isoelectric point of 3.95+0.15 and a specific aminoacid composition, the N-terminal, if appropriate, carrying an acyl group or an acylglycyl group, processes for its isolation and purification, its use, agents containing this polypeptide, and its cleavage products, their use and agents containing them.Type: GrantFiled: July 3, 1984Date of Patent: July 2, 1985Assignee: Hoechst AktiengesellschaftInventors: Gerhard Seipke, Dominique Tripier, Gerd Johnscher
-
Patent number: 4500450Abstract: The invention relates to a polypeptide which can be isolated from thymus glands and has an action on the immunological system, and which has a molecular weight of 3,480, a UV absorption with a maximum at 205 to 210 nm and an isoelectric point of 3.95+0.15 and a specific aminoacid composition, the N-terminal, if appropriate, carrying an acyl group or an acylglycyl group, processes for its isolation and purification, its use, agents containing this polypeptide, and its cleavage products, their use and agents containing them.Type: GrantFiled: August 11, 1983Date of Patent: February 19, 1985Assignee: Hoechst AktiengesellschaftInventors: Gerhard Seipke, Dominique Tripier, Gerd Johnscher